ONCAlert | Upfront Therapy for mRCC

Bladder Cancer 1 MORE >>

Vicinium has demonstrated positive 12-month complete response rate findings in the VISTA trial of patients with high-risk patients with non–muscle-invasive bladder cancer who were unresponsive to bacillus Calmette-Guérin treatment, according to updated preliminary findings from the phase III clinical trial.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.